I believe it was Bridge-to-Sell - what happened to the recent post (either YMB or SA board) loosely tying Geron's potential value to Sierra's? It seems to have disappeared into the darkness. I'd like to revisit that in-light of this new acquisition and price.
https://investor.sierraoncology.com/new ... fault.aspx
GSK-Reaches-Agreement-to-Acquire-Late-Stage-Biopharmaceutical-Company-Sierra-Oncology-For-1.9bn
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: GSK-Reaches-Agreement-to-Acquire-Late-Stage-Biopharmaceutical-Company-Sierra-Oncology-For-1.9bn
Momelotinib has an interesting history. It was developed by an Australian biotech years ago. That company was bought by YM BioSciences in 2011, and YM BioSciences was bought by Gilead in 2013. In 2018, Sierra Oncology bought momelotinib off the scrap heap from Gilead for only $3 million upfront, with the promise of an additional $195 million in various future milestone payments and tiered royalties from the mid-teens to the mid-twenties.
As far as using Sierra as a valuation comparable, momelotinib is a front-line drug that has the potential to be a real competitor to ruxolitinib. Plus, Sierra has a couple early-stage BET inhibitors under development. Regardless, its acquisition by GSK shows there’s plenty of money floating around out there looking for good, approvable drug candidates in the blood cancer space.
As far as using Sierra as a valuation comparable, momelotinib is a front-line drug that has the potential to be a real competitor to ruxolitinib. Plus, Sierra has a couple early-stage BET inhibitors under development. Regardless, its acquisition by GSK shows there’s plenty of money floating around out there looking for good, approvable drug candidates in the blood cancer space.